Dr Reddy’s launches generic version of Plaquenil in US
Team Udayavani, Jul 11, 2018, 4:39 PM IST
New Delhi: Dr Reddy’s Laboratories today announced the launch of generic version of Plaquenil, used to treat malaria, lupus erythematosus, and rheumatoid arthritis, in the US.
The launch follows approval of Hydroxychloroquine Sulfate tablets, a therapeutic equivalent generic version of Plaquenil, by the US Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a BSE filing.
Quoting IMS Health data, Dr Reddy’s Laboratories the Plaquenil brand and generic had US sales of approximately USD 215 million for the most recent twelve months ending in May 2018.
Dr Reddy’s said its product Hydroxychloroquine Sulfate tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil is a trademark of Concordia International Corp.
Shares of Dr Reddy’s Laboratories were trading at Rs 2,293.95 apiece, down 1.11 per cent from the previous close on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
RBI announces MPC schedule for FY25, first rates decision on April 5
Seven out of ten Indian shoppers say they would happily receive product deliveries without additional packaging
Renault Nissan to launch four new products, expand product portfolio
Sensex, Nifty rebound on heavy buying in Reliance Industries, HDFC Bank
IndiGo to fly more international routes, destinations; aims doubling size by 2030: CEO Pieter Elbers
MUST WATCH
Latest Additions
Rs 20.14 cr unaccounted cash seized in poll run up in Karnataka
HC grants bail to man held for sexually assaulting ‘friend’ at Mumbai beach in 2021
Congress’s Kolar conundrum remains unsolved despite CM, DCM attempt to quell dissent
Mangaluru: Illegal slaughterhouse raided by police, Three arrested
‘No evidence of wrongdoing’: CBI closes UPA-era Air India aircraft leasing